Global Erectile Dysfunction Drugs Market 2014-2018 is a new market research publication announced by Reportstack. A man's failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to stress, anxiety, and self-confidence problems. New research is undergoing in the field of erectile dysfunction to find more enhanced and effective therapies.

The analysts forecast that the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Erectile Dysfunction Drugs market for the period 2014-2018. The Global Erectile Dysfunction Drugs market can be divided into six segments: PDE 5 Inhibitors, Vacuum Constriction Device, Penile Prosthesis, Vascular Reconstructive Surgery, Injection Therapies, and Testosterone Replacement Therapy. To calculate the market size, the report considers the revenue generated from the sales of various drugs and topical creams used for the treatment of erectile dysfunction.

The report Global Erectile Dysfunction Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Erectile Dysfunction Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• APAC
• EMEA 
Key Vendors
• Apricus Biosciences
• Bayer
• Dong-A Socio Holdings
• Eli Lily
• Pfizer
• Vivus 
Other Prominent Vendors
• Auxillium Pharmaceuticals
• Cristalia Produtos Quimicos Farmaceuticos
• Futura Medical
• Johnson & Johnson
• Meda Pharmaceuticals
• Pacific Therapeutics
• Seattle Genetics 
Market Driver
• Increase in Aging Population
• For a full, detailed list, view our report
Market Challenge
• High Cost
• For a full, detailed list, view our report
Market Trend
• Increased Awareness of Erectile Dysfunction
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


Companies Mentioned

Apricus Biosciences,Bayer,Dong-A Socio Holdings,Eli Lily,Pfizer,Vivus ,Auxillium Pharmaceuticals,Cristalia Produtos Quimicos Farmaceuticos,Futura Medical,Johnson & Johnson,Meda Pharmaceuticals,Pacific Therapeutics,Seattle Genetics

To view the table of contents and know more details please visit Global Erectile Dysfunction Drugs Market 2014-2018.